Analyzing RNA‐seq samples from a historical cohort of AML patients receiving HiDAC‐Mito only therapy revealed that neither the estimated abundance of NK cells nor the expression of NK cell signature was correlated with response to HiDAC‐Mito only therapy (Figure S3B,C, Supporting Information).[6] We also assessed the expression of known NK cell marker genes NCR1, KLRD1, NKG7, and KLRC3, which were upregulated in responders of AZA‐HiDAC‐Mito therapy but not HiDAC‐Mito therapy, compared to non‐responders (Figure S3D, Supporting Information). The gene discussed is NCR1; the disease is acute myeloid leukemia.